Proteomics

Dataset Information

0

Human stool (IBD patients, LC-MS/MS)


ABSTRACT: Fecal samples (n=52) of a cohort of IBD patients were collected before and after 14 weeks of treatment with three different biologics. Clinical disease activity scores were used to determine the clinical response and remission. Fecal metaproteomes of remitting patients (n=12) and of non-remitting patients (n=12) were compared before treatment and changes within both groups were assessed over sampling time to identify functional changes and potential human and microbial biomarkers. (2 patients were excluded from finala analyses as the started the therapy in a remitting disease state.)

INSTRUMENT(S):

ORGANISM(S): Human Gut Metagenome

DISEASE(S): Inflammatory Bowel Disease

SUBMITTER: Maximilian Wolf  

LAB HEAD: Prof. Dr. Robert Heyer

PROVIDER: PXD053257 | Pride | 2026-03-20

REPOSITORIES: pride

Dataset's files

Source:
Action DRS
12A.d.zip Other
12A.dat Other
12A.mgf Mgf
12B.d.zip Other
12B.dat Other
Items per page:
1 - 5 of 156
altmetric image

Publications


The gut microbiome is an important contributor to the development and the course of inflammatory bowel disease (IBD). While changes in the gut microbiome composition were observed in response to IBD therapy using biologics, studies elucidating human and microbial proteins and pathways in dependence on therapy success are sparse. Fecal samples of a cohort of IBD patients were collected before and after 14 weeks of treatment with three different biologics. Clinical disease activity scores were use  ...[more]

Similar Datasets

2016-07-25 | E-GEOD-78724 | biostudies-arrayexpress
2022-10-13 | PXD034175 | Pride
2025-12-18 | PXD068250 | Pride
2011-02-01 | E-GEOD-25220 | biostudies-arrayexpress
2023-05-04 | E-MTAB-11150 | biostudies-arrayexpress
| PRJEB53582 | ENA
2015-08-06 | E-GEOD-71726 | biostudies-arrayexpress
2025-08-08 | PXD057701 | Pride
2025-06-10 | PXD058570 | Pride
2025-05-15 | PXD058659 | Pride